Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Mazdutide cycle length: what human studies ran

Approved outside the USAHuman trial evidence
Short answer: there is no established Mazdutide cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. GLORY-1: 48 weeks; GLORY-2: 60 weeks 1,5.
  2. Type 2 diabetes phase 3: 24 weeks plus a 24-week extension (placebo-controlled) and 28 weeks (DREAMS-2) 3,4.
  3. US phase 2: 48 weeks, primary endpoint at 32 weeks 7.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Mazdutide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Mazdutide cycle length?
No. Human studies administered Mazdutide for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Mazdutide?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Mazdutide dosing reference Full research page

References

  1. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1) N Engl J Med. 2025
  2. Mazdutide: First Approval Drugs. 2025
  3. Mazdutide versus placebo in Chinese adults with type 2 diabetes Nature. 2026
  4. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes (DREAMS-2) Nature. 2026
  5. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial JAMA. 2026
  6. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity Nat Commun. 2023
  7. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial Lancet Diabetes Endocrinol. 2026
  8. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study EClinicalMedicine. 2021
  9. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes Nat Commun. 2022
  10. Drugs@FDA application data queried through openFDA for mazdutide (no matching application record returned on 23 October 2026) openFDA / Drugs@FDA. 2026
  11. PubChem compound record for mazdutide (CID 167312357; CAS 2259884-03-0) PubChem. 2026
  12. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
  13. A Study of IBI362 in Participants With Obesity or Overweight (GLORY-1) ClinicalTrials.gov. 2024
  14. A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise (DREAMS-1) ClinicalTrials.gov. 2024
  15. A Study of IBI362 in Participants With Type 2 Diabetes (DREAMS-2) ClinicalTrials.gov. 2024